



## Recently Introduced Products

Drug Name	Indication	Potential Impact	Expected Avg. Annual Cost
Micardis Plus 80/25 mg	Treatment of patients whose blood pressure is not adequately controlled by Micardis Plus 80/12.5 mg or patients who have been previously stabilized on Micardis and hydrochlorothiazide separately	\$	\$413
Tecta	Treatment of conditions where a reduction in gastric acid secretion is required such as reflux esophagitis and nonerosive reflux disease (i.e. heartburn and regurgitation)	\$\$	\$504

\$: Est. drug plan expenditure increase of <1%\* \$\$: Est. drug plan expenditure increase of 1-5%\* \$\$\$: Est. drug plan expenditure increase of >5%\*

## Prolastin® - Expanded Access to Treatment of Alpha<sub>1</sub>-Antitrypsin Deficiency-Related Pulmonary Disease

Prolastin is indicated for pulmonary emphysema associated with alpha<sub>1</sub>-antitrypsin deficiency (AATD). Alpha<sub>1</sub>-antitrypsin is an enzyme that protects against the natural degradation of lung tissue. AATD results in a greater than 80% life-time risk of developing pulmonary emphysema, starting as early as the 3<sup>rd</sup> and 4<sup>th</sup> decade of life. Emphysema results in shortness of breath, disability, poor quality of life and early death<sup>1, 2</sup>. Based on a prevalence of approximately 1 in 6,000 Canadian adults, AATD is considered relatively rare. However, it is believed that only 5% of the affected population is diagnosed<sup>3</sup>.

Prolastin, a drug administered intravenously, has been available in Canada since 1991. Since Prolastin is a product derived from human plasma, its availability has been restrained by limited plasma supply. Recent increases in plasma collection have permitted full commercialization of Prolastin in Canada. Although accumulated observational studies suggest that Prolastin may slow down degradation of the lungs, reduce the frequency and severity of bronchial infections and reduce mortality, further long-term studies are required to confirm clinical benefits of this therapy<sup>3</sup>.

The annual cost of treatment with Prolastin is approximately \$80,000 to \$100,000. Currently, Prolastin is reimbursed through the Ontario, Quebec and Manitoba provincial drug program following case-by-case review. In B.C., Prolastin is covered without restriction<sup>3</sup>. For patients outside these provinces, without a private reimbursement option, Prolastin may be available through ProlastinDirect, a funding program sponsored by the manufacturer<sup>2</sup>. Since Prolastin is an IV injection and is administered primarily in a hospital setting, it is excluded from all ClaimSecure Drug Benefit Plans.

*Should you wish to cover Prolastin® under your plan, please contact your Client Services Associate. If you require additional information about Prolastin®, please contact Shellina Sevany, Manager, Clinical Services Department, at (905) 949-3025 or 1-888-479-7587 ext.3025.*

### Recommendation: Exclude

*ClaimSecure reserves the right to amend in part or in its entirety stated special authorization clinical guidelines*



claimsecure.com / securindemnite.com

References:  
1) Alpha-1 Antitrypsin Deficiency. [http://en.wikipedia.org/wiki/Alpha\\_1-antitrypsin\\_deficiency](http://en.wikipedia.org/wiki/Alpha_1-antitrypsin_deficiency). Accessed January 5, 2009.  
2) Prolastin. <http://www.prolastin.com/>. Accessed January 5, 2009.  
3) Prolastin® Private Payer Submission Binder. Talecris Biotherapeutics October, 2008.

\* Based on the Financial Impact Analysis per 100 000 lives covered  
© 2008 ClaimSecure Inc.